Skills Shortages could Scupper Singapores Growth Prospects
As increasing numbers of pharmaceutical companies expand into Singapore, and businesses experience high levels of staff movement as a result of heightened confidence amongst jobseekers, future growth could be affected by a marked skills shortage. That’s according to the latest Global Sentiment Survey from Berkley Group, which analyses employment and market perceptions internationally.
People Crisis Looms for Pharma Companies
Recent reports from the Ministry of Trade reveal that the Singapore economy grew 5.4% in Q1 2014 which has, in turn, led to increased investment in the region and heightened confidence amongst jobseekers and employers alike. Despite this, however, Berkley’s research reveals that future growth may be halted by a lack of available talent. The report revealed that 80% of the current workforce intends to move jobs in the next year, with 60% planning to do so within 6 months. This is in keeping with recent research from Sylvia Vorhauser-Smith, Senior Vice President of Research at PageUp People, which reveals that regular job hopping is prevalent in the country’s workforce.
Robust Attraction and Retention Strategy a must for Employers
This high level of predicted movement amongst the workforce is likely to exacerbate the already present concerns surrounding talent retention and attraction in Singapore. This, coupled with increasing pressure mounted on employers to hire locals before expats, means that staffing strategies need to be far more succinct to help organisations attract and retain those professionals with the requisite skill sets to prevent a slowdown in growth. This is a sentiment mirrored in Berkley’s research which reveals that, whilst 90% of those surveyed expect a pay rise in the coming year, very few reported financial incentives as a contributing factor in moving jobs (30%). In comparison, 57% acknowledged that career progression would be the biggest driver. These results suggest there is currently a significant disconnect between staff preferences and workplace incentives.
Wendy Cheong, Practice Director at Berkley Group, comments: “The Singapore economy is currently experiencing a period of intense change as plans for economic development and growth remains a high priority for the government. However, for businesses to remain competitive, it’s vital that they have the right talent on board, an objective that has long been a challenge with high levels of staff turnover and a heavy reliance on expats in the country. As recruitment activity looks set to increase, there will need to be a change in the mindset of employers to ensure they are providing the right opportunities to attract and retain staff to prevent marked skills shortages. As financial incentives continue to drop off the radar of the workforce, perhaps career development opportunities need to be considered as part of the talent attraction strategy.”
To see the report visit www.berkley.com.sg/research-download
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance